Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer
- 1 May 2016
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 107, 29-40
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81402957)
- Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study (BZ0150)
- National Major Scientific and Technological Special Project (2012ZX09301002-006)
This publication has 43 references indexed in Scilit:
- New approaches for improving outcomes in breast cancer in EuropeThe Breast, 2015
- DNA Damage in Cancer Therapeutics: A Boon or a Curse?Cancer Research, 2015
- Protein ADP-ribosylation and the cellular response to DNA strand breaksDNA Repair, 2014
- PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1Nucleic Acids Research, 2014
- The breast cancer susceptibility genes (BRCA) in breast and ovarian cancersFrontiers in Bioscience-Landmark, 2014
- Large-scale preparation and characterization of poly(ADP-ribose) and defined length polymersAnalytical Biochemistry, 2012
- Increased PARP-1 Association with DNA in Alkylation Damaged, PARP-Inhibited Mouse FibroblastsMolecular Cancer Research, 2012
- The Association Between Biological Subtype and Isolated Regional Nodal Failure After Breast-Conserving TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancerCancer, 2007
- Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastasesBreast Cancer Research and Treatment, 2006